Growth Hormone Deficiency Market Size, Share, Trends, Analysis, COVID-19 Impact Analysis and Forecast 2024-2031 The research includes detailed information on new market trends, market drivers, development opportunities, and restraints that may affect the industry's market dynamics. It provides a thorough examination of the product, applications, and competitive landscape in the market segments. The Growth Hormone Deficiency market research study includes strategy analysis, trend and scenario analysis for micro and macro markets, pricing analysis, and a comprehensive summary of the market position throughout the forecast period. Primary and secondary drivers, market share, critical areas, and regional analysis are all included in this study. It's a thorough and professional report. Primary and secondary research methodologies were used to investigate the Growth Hormone Deficiency market from all angles. It assisted us in comprehending market dynamics such as supply-demand imbalances, price trends, product preferences, and customer behaviors, among other things. Their findings were subsequently corroborated by primary research with industry professionals and opinion leaders in several nations. The data is then gathered and evaluated using various market estimates and data validation procedures. We also have an internal data prediction model that we use to forecast market growth. Sample report https://www.snsinsider.com/sample-request/2654 Market Segmentation The Growth Hormone Deficiency research report discusses market segmentation by product category, application, end-user, and geographic area. The market research study examines, analyses, and presents each sector and sub-segment of this market. This segmental analysis will help market players to gain insights regarding the highly performing segments where they can focus more to generate higher revenues from their business. Regional Overview According to the regional study, the Growth Hormone Deficiency market is divided into the following main geographical regions: North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. The study goes into great detail about production and consumption ratios, market size and share, import and export, and infrastructural development in each region. Major Objectives of Growth Hormone Deficiency Market Report • Potential and specialty segments, as well as growth-oriented regions • Historical, present, and projected market size • An objective view of market performance • Prospects for industry participants and stakeholders in the future • Industry drivers, constraints, and research possibilities • Current industry trends and developments • Strategies for important players and a competitive countryside Key Reasons to Purchase Growth Hormone Deficiency Market Report • The research includes critical information such as a market dynamics situation and forecast period prospects. • Market influence, demand, and supply forces are included in regional, sub-regional, and country statistics. • The segments and sub-segments include quantitative, qualitative, value, and volume data. • A variety of significant players, new advances, and strategies are all part of the competitive environment. • Comprehensive product companies, essential financial data, current events, SWOT analysis, and strategies of top players. Report Conclusion The market research report contains a long-term forecast, current trends and drivers, and an up-to-date analysis of the industry's expanding global structure. Key players Major Players are Eli Lilly and Company, Roche, Ipsen, Ferring B.V., Novo Nordisk A/S, Pfizer, Inc, Teva Pharmaceutical Industries, Ltd, Merck KGaA ,Novartis AG, and Others Players. Contact info Akash Anand – Head of Business Development & Strategy info@snsinsider.com Phone: +1-415-230-0044 (US) | +91-7798602273 (IND) Related Reports https://www.snsinsider.com/reports/blockchain-technology-in-healthcare-market-2196 https://www.snsinsider.com/reports/healthcare-asset-management-market-2195 https://www.snsinsider.com/reports/healthcare-claims-management-market-2194 https://www.snsinsider.com/reports/medical-device-security-market-2193 https://www.snsinsider.com/reports/anatomic-pathology-track-and-trace-solutions-market-2147

Exosome Therapeutics Market 2022 – Industry Growth by 2035 In recent years, therapies utilizing extracellular vesicles have garnered significant attention among the industry stakeholders for the treatment of diverse target indication, primarily owing to the various benefits offered by them, including target specificity, enhanced tissue regeneration, and reduced inflammation and chronic pain. Over time, various research studies have demonstrated the potential of exosomes (membrane bound extracellular vesicles) in disease diagnosis, drug delivery and therapeutic applications. As a result, exosome therapeutics domain has been gaining traction recently. INTRODUCTION TO EXOSOMES Exosomes are extracellular vesicles, which have endosomal origin and may contain different biomolecules, including proteins, DNA, lipids, miRNA or RNA, based on the type of cell of their origin and its conditions. Exosomes convey a wide range of information to the target cells, depending on their source. In addition, they are involved in regulating the expression of the targets that are linked to RNA as they can affect the expression of RNA. TYPES OF EXTRACELLULAR VESICLES Micro-vesicles have size of about 100 nm and are formed by direct outward budding of the plasma membrane. Their formation solely depends on the surrounding environment and this process requires the presence of cytoskeleton components, namely actin/ Exosomes have a diameter in the range between 30-150 nm and are formed by inward budding and get developed into the multivesicular bodies (MVBs). Owing to their long half-life, exosomes can target specific organs of the body, which makes them widely studied vesicles for immunological purposes. Apoptotic bodies have a diameter of about 5,000 nm and formed after the separation of plasma membrane from the skeleton. They can be easily distinguished from micro vesicles and exosomes because of their unscathed organelles as well as chromatin. EXOSOME BIOGENESIS, FORMATION, DEVELOPMENT AND SECRETION Exosomes are known to arise from the inward folding of multi-vesicular bodies (MVBs) in order to form the intraluminal vesicles (ILVs). These MVBs are then delivered to the trans-Golgi network (TGN) for the recovery of endosomes, which further move to lysosome for degeneration of the carried substances. The most essential component of exosome biogenesis is the formation of ESCRT. Formation and development of exosomes:  Sorting of internalized cargoes into early endosomes  Maturation into late endosomes or multivesicular bodies  Delivery of cargoes from trans-Golgi network and cytosol  Exosomes cargo in multivesicular bodies are transported to plasma membrane  Fusion with the plasma membrane  Secretion of exosomes ADVANTAGES AND FUTURE POTENTIAL OF EXOSOME THERAPEUTICS: Advantages:  High Compatibility: Exosomes are naturally occurring compounds that can withstand digestive enzymes.  Low Immunogenicity: Due to the innate properties of exosomes including their potential tissue of cell selectivity.  Targeted Drug Delivery: Ability to cross blood brain barrier cause lesser systemic effects and low toxicity. Future Potential:  Several emerging players have undertaken initiatives to explore the potential of exosomes for diagnosis of various diseases.  Application of exosomes as biomarker or vector of various potential therapeutic molecules, represents a theragnostic approach.  Advanced exosome technologies are being developed to fully substructure the potential therapeutic applications of exosomes. For additional details, please visit https://www.rootsanalysis.com/blog/introduction-to-exosome-therapeutics/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities The application of digital twins in healthcare has the potential to revolutionize patient care, improve clinical outcomes, and reduce costs. Digital twins, or virtual replicas of physical objects and environments, are being used in many different industries, and healthcare is no exception. In healthcare, these can be used to provide better patient monitoring, improve remote care, and create personalized treatments. What is a Digital Twin? Digital twins are virtual representations of real-world objects. A digital twin is a piece of equipment, for example, may have the same functionality as the physical counterpart. Digital twins can be created using a wide range of data sources, such as sensors, models, and images. In the context of healthcare, these technologies can include the full representation of a patient’s medical history, symptoms, current treatment, and even biometric data, such as blood pressure and heart rate. Benefits Associated with The Use of Digital Twins Digital twins offer many benefits to the healthcare industry. In the following sections, we explore the top three benefits offered by digital twin technologies. • Real-Time Data Access – While physical objects can be monitored and controlled, the data is often delayed. A digital twin, on the other hand, can be almost immediately updated with data. This means that healthcare providers can see and respond to real-time changes / real world evidence and abnormalities. • Improved Remote Care – Remote care is when healthcare is provided to patients who are not physically in a healthcare facility. Remote care is growing in popularity, but it comes with several challenges, such as a lack of real-time data and an inability to supervise the patient. Digital twins can help with these challenges by providing real-time data and allowing healthcare providers to view the patient remotely (telemedicine support). Disadvantages Associated with The Use of Digital Twins For all the benefits of digital twins, there are still some challenges that need to be addressed. In the following sections, we explore the top three challenges. • Difficulty in Adoption – Digital twins have been in use since the early 2000s, but they have only recently started to be used in healthcare. This is largely due to the fact that digital twins have been primarily used in industrial settings and that the concept has been hard for healthcare providers to grasp. While many find the concept of a digital twin attractive, it has been challenging for healthcare providers to adopt the concept. • Possibility of False Information – When data is fed into a digital twin, it can be inaccurate or incomplete. This can lead to incorrect findings and incorrect treatment plans. However, there are some efforts underway to solve this problem. One approach is to make the data used to create the digital twin as accurate as possible. Another approach is to let the digital twin correct itself based on new data. Future Perspectives In the following sections, we explore three ways in which the use of digital twins in healthcare can be improved. • Better Adoption Rates – With better adoption rates, healthcare providers will be able to use digital twins to their full potential. With the help of vendors and organizations, such as the Industrial Internet Consortium, healthcare providers can be better informed about the advantages of digital twins. Despite their immense rise in popularity, digital twins still have some issues that need to be resolved. As such, there are some ways in which the use of digital twins in healthcare can be improved. For additional details, please visit https://www.rootsanalysis.com/blog/digital-twins-in-healthcare/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Adeno-Associated Viral Vectors: Unlocking the Future Opportunities Given the potential of gene therapies in targeting the underlying cause of a disease at cellular level, the demand for such therapies has increased considerably over the past few years. Currently, more than 285 gene therapies are being evaluated in different phases of clinical development. Further, various gene therapy developers have raised more than USD 10 billion capital during the year 2021. With the growing interest in such therapies, the demand for novel delivery vectors has also increased. Among various gene delivery vectors available, adeno-associated viral vectors have emerged as one of the most efficient viral vectors. Till now, the USFDA has approved two adeno-associated viral vectors-based drugs, LUXTURNA® and ZOLGENSMA®. In order to cater to the demand, close to 100 players, across the globe, have emerged for the development and manufacturing of adeno-associated viral vectors. In fact, a number of these companies also offer advanced technology platforms, enabling the processing of AAV vectors and related therapies across different scales of operation. Various industry and non-industry players are actively engaged in research and development of novel gene delivery technologies, which are safe and effective. 155+ Clinical Trials have been / are being conducted The stakeholders have invested extensively in conducting clinical trials for evaluating the efficacy of the therapeutic candidates in the treatment of a variety of indications. ~4,300 Patent Filed / Granted in the Domain Examples of leading industry stakeholders, in terms of most patent applications filed include Genzyme, Voyager Therapeutics, REGENXBIO, Baxalta and Spark Therapeutics. 200+ Partnerships and Collaborations signed in the Domain The growing partnerships and collaborations signed between different stakeholders is indicative of the significant demand of vectors and related therapies from the past few years. As projected by Roots Analysis, oncological disorders therapeutic area will have majority share in the adeno-associated viral vector market. As projected by Roots Analysis, the overall market of AAV vector manufacturers market is expected to expand in the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/adeno-associated-viral-vector/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Modular Construction – Retrofitting Conventional Buildings Shifting construction away from traditional sites and into factories could dramatically change the way we build. Will off-site builds bolster construction this time around? Over the years, construction has straggled behind other sectors in terms of efficiency. Off-site builds or modular construction is a powerful way to reform construction business saving more time, labor, cost and productivity mutually benefitting the manufacturer as well as the customer. What is Modular Construction? Modular Construction is a process in which different components known as Modules are constructed in a controlled factory setting and later assembled on the desired site as per the requirement of the user. In general, 60% to 90% of the work is completed offsite while the rest on the location where the facility is needed. The factory-made, standard modules are accustomed with walls, doors, ceilings, frames, and windows. Additionally, the modules can be integrated with more specific components, such as air handling units, fan filter units, air showers along with the lighting and plumbing facility intended for pharmaceutical use. It is worth mentioning, majority of the modular facilities built are GMP certified ensuring required quality standards have been met while construction. Types of Modular Construction Modular Construction can be broadly categorized into two categories, namely permanent and relocatable. Permanent modular builds mean the facilities are constructed to be used at the same location wherein it has been assembled. In other words, the building is similar to conventionally constructed infrastructure except the fact it has been built off-site. Need for Modular Facilities Conventional construction has never shown to surpass 80% mark owing to factors including logistical delays, type of material used, method of construction adopted and shortage of manpower eventually hampering the productivity. Whereas prefabricated approaches have reported to increase productivity by more than 100%. Modular construction acts as a sustainable method empowering today’s construction sector. The Modular Construction Process In the first phase, a description of the building that is to be constructed is created through discussion between the customer and modular building manufacturer followed by review of the engineering department to evaluate whether the proposed design meets all the applicable building codes. Then, granting of building permit is required in most jurisdictions for constructing new structures, or performing major renovations. Modular Construction in Pharmaceutical Industry The concept of modular construction has been used in other industries for a long time; however, over the past two to three decades, it has only gained significant attention within the pharmaceutical industry. Moreover, there is immense pressure on drug manufacturers to market novel drugs as soon as possible, before patent expiry. Increased pressure to expedite time to market, coupled with the need to decrease operating costs and increase manufacturing efficiencies, have amplified the value of smaller production facilities, which are more efficient and flexible. The modular construction market developments have made modular facilities more attractive to drug manufacturers today, as these facilities can quickly switch between multiple drugs, enabling formulation and packaging in multiple formats, such as solid, liquid, semi-solid and parenteral dosage forms. Roadblocks to Headway It is evident that shifting from conventional on-site construction to off-site modular construction can fundamentally avoid unforeseeable risks. However, on the other hand, construction of modular facilities may face certain challenges, in order to maintain the essentials of design and equipment of the facility. Some of the challenges with this approach may involve factors, such as logistics constraints, transportation, safety permits and communication barriers. For additional details, please visit https://www.rootsanalysis.com/blog/modular-construction-in-pharma-industry/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Long-Acting Drug Delivery: A Novel Pharmacological Strategy to Deliver Therapeutic Modalities LADD has emerged as the novel and advanced drug delivery system which manipulate the dosing regimen of the drug in the body in order to sustain its therapeutic level. Over the last two decades, the pharmaceutical industry has observed a paradigm shift from conventional drug delivery strategies to the long-acting drug delivery (LADD) of products to treat several disease indications, such as ophthalmic disorders, oncological disorders, neurological disorders and infectious diseases. These novel systems circumvent the limitations of conventional drug delivery system, such as multiple dosing frequency, fluctuating plasma levels, high toxicity levels and poor patient compliance. Principles and Strategies associated with Long-Acting Drug Delivery Lately, many technologies are being explored to develop long-acting drug in various dosage formats, such as long-acting injectables, depot injections, implantable devices and combination products. The LADD technologies have come a long way with the inclusion of liposomes, microspheres and polymers for the fabrication of biodegradable and biocompatible delivery system. Apart from this, the interdependency of drug, excipient and release environment plays a crucial role to decide the release kinetics of the drug. What are the Benefits of Outsourcing to Contract Service Providers (CDMOs / CDOs / CMOs)? One of the critical factors associated with the development of long-acting drugs is the selection of drug therapeutic window and its absorption characteristics. It also encompasses the quantitative determination of drug metabolism and pharmacokinetic (DMPK) properties. In addition, the formulation of these drugs is a complex process, especially if there is inclusion of highly potent molecules. Some of the other challenges include aseptic manufacturing, terminal sterilization, suitable characterization methods, lack of GMP-certified facilities and specialized equipment. Owing to the advanced LADD technologies, formulation and developmental challenges associated with these complex dosage forms, the reliability on stakeholders having the expertise in this domain has upsurged. This will eventually aid the drug developers to address the bottlenecks stemming from conventional treatment options and improve the clinical outcome. Bottom Line Keeping every trend in mind, Roots Analysis has provided complete information on market trends in long-acting drug delivery domain, which has some of the very recent and precise activities listed for the clients to help them make better decisions in its report titled, Long-Acting Drug Delivery Technologies and Services Market, 2023-2035. To find answers to key decision-making question and to know further about the market forecast analysis, highlighting the likely growth of the long-acting drug delivery technologies and services market, for the time period 2023-2035. For additional details, please visit https://www.rootsanalysis.com/blog/long-acting-drug-delivery-technologies/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Digital Therapies: The “Digital Pills” of current generation As per United Nation’s report, the current global population stands at around 8 billion and expected to reach 9 billion by the end of 2030. This increase in population is accompanied with a rise in the incidence of several chronic disease indications. In fact, as per a report published by National Association of Chronic Disease Director, by 2030 this increase of the chronic condition would cost the US economy about USD 2 trillion. Furthermore, the lack of medical awareness and vulnerability in the medical infrastructure is believed to make the things more complicated in the coming future. Therefore, in order to cater this need, a number of stakeholders have come up with the innovative solution of digitizing the healthcare industry with next generation tools, such as artificial intelligence, digital therapies, telemedicine, electronic health records and others. It is worth noting that these next generation techniques have demonstrated significant potential to improve the quality of lives of individuals suffering from chronic conditions. What is Digital Therapeutic? Digital Therapeutics is one of the many new initiatives undertaken by the stakeholders to cater the growing need. As per Digital Therapeutics Alliance, digital therapeutics is a software-based intervention to patients to treat, manage or prevent a disease or disorder. These therapeutics are designed to engage patients in personalized treatment or disease prevention programs, through mediating behavioral or psychological modifications, providing motivational support and inculcating healthy lifestyle changes. Moreover, in order to be at par with the conventional medicines, several organizations have taken the initiative of validating their product in clinical trials for its safety and efficacy. In fact, the term “digital pills” has been coined due to its ability to compete against the conventional medicines/drugs. Furthermore, several organizations have undertaken key diverse initiatives in the field of digital therapies to support its growth as a new frontier in the healthcare sector. For instance, several organizations are focused on the development of prescription digital therapeutic solutions, wherein the product is prescribed by healthcare professionals or clinicians after confirmation of the eligibility of patients for using such solutions. In addition, to make digital therapeutics more engaging, these are currently being offered in a combination of software applications and others such as gaming solution, personal coach, and AI support. It is worth mentioning that the ease of use, personalized experience, accessibility, and convenience coupled with the COVID-19 pandemic, has popularized the digital therapeutics among the general population. In fact, countries, such as United States, Germany, UK, and others now have come up with their own laws to regulate the digital therapeutics among its population. For instance, in United States, the USFDA has implemented “Breakthrough Device Designation Program” for regularizing digital therapies as a medical intervention / solution for various indication. Likewise, UK have NHS based digital therapeutics database, wherein clinicians can refer for prescribing products and Germany has “Digital Health Act-2019”, for regularization of digital therapeutics. Bottom-Line Amidst growing competition, the availability of cutting-edge tools and technologies have emerged as a differentiating factor. This has caused many big pharma companies to actively expand their service portfolios, either through strategic acquisitions or entering into alliances with other digital therapeutic developers. Recent examples include AstraZeneca’s collaboration with digital therapeutics developer my health, wherein both the companies integrated their proprietary products for better outcome. You can also check out our report on digital therapies by visiting ‘digital health market ‘section. For additional details, please visit https://www.rootsanalysis.com/blog/digital-therapies-the-digital-pills/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Demand for Outsourcing Biologics Fill Finish Services The increasing demand for biologics has led to an increasing need for production capacity, which is characterized by high quality standards. Although, it is a challenging field, outsourcing has emerged as a promising segment, especially for drug product manufacturing and aseptic fill / finish operations. Despite being one of the crucial steps of all the steps involved in the production of biologics, fill finish is heavily outsourced activities in the pharmaceutical industry. Currently, it is estimated that more than 50% of the overall operations are outsourced to service providers. Service providers offering these services are using vials for filling of biologics. Of these, over 70% of service providers operate at clinical and commercial scales of operation. Of the players offering these services for biologics are headquartered in Asia-Pacific. More than 35% of these players are located in China. Further, of these, more than 40% players are well established players. Expansions have been witnessed by the industry, since 2013 to cater to the increasing need of their clients; of these, 55% expansions are associated with the establishment of new facility or adding area to the existing facility. Of global biologic fill finish capacity available in the facilities established by services providers is for filling of vials. Further, majority of capacity is available with service providers headquartered in Asia-Pacific. As projected by Roots Analysis, antibodies will have the highest share in this market. This trend is likely to continue in the future. In addition, majority of the market is likely to be driven by the filling of vials and syringes. More than 35% of these service providers are headquartered in Europe. Over 20% of these players were established before 1960 and 45% of the players were established after 2000. With outsourcing being increasingly accepted as a viable / beneficial business model and the anticipated growth in the biologics market, the opportunity for fill finish biopharmaceuticals service providers is expected to grow at a steady pace over the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/demand-for-outsourcing-biologics-fill-finish/ You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

TIL Therapies: A New Paradigm in Cancer Treatment Till date, several clinical trials have demonstrated the efficacy and therapeutic superiority (over conventional treatment options) of TIL-based therapies. Modified tumor-infiltrating lymphocytes or TIL therapies have emerged as a viable and potent option to selectively eradicate the tumor population, with minimal side effects. Their tumor-cell killing efficiency is attributed to the fact that they are pre-sensitized to cancer specific antigens. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the TIL-based therapy market is likely to witness significant growth in the foreseen future. Current Market Landscape of TIL-based Therapies Over 75 TIL immunotherapies are being evaluated across different stages of preclinical / clinical development, either as monotherapies or in combination with other drugs. Both industry and non-industry players have demonstrated keen interest in the development of novel TIL-based cell therapies. Further, melanoma emerged as the most popular target indication in this domain. More than 95% of the therapy candidates that are being developed to target a wide range of disease indications are autologous in nature. Driven by a promising development pipeline and encouraging clinical trial results, the TIL therapy market is likely to carve out a significant share of the multibillion-dollar cancer immunotherapy market. Rising Interest in TIL-based Therapies The growing interest in this field is therapies is reflected from the increase in the partnerships focused on R&D of such therapies. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 2.7 billion, across 30 instances, since 2013. Further, in the last 10 years, close to 95 clinical trials evaluating TIL-based therapies have been registered across different geographies for the evaluation of TIL-based therapies. Mostly driven by the need for effective treatment options for cancer, the TIL-based therapy pipeline is expected to steadily grow over the coming years. For additional details, please visit https://www.rootsanalysis.com/blog/til-based-therapies/ or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

Artificial Intelligence (AI) In Oncology: Current Scenario and Future Potential In the last decade, the popularity of AI has grown invariably. It has made a considerable impact in the medical sector and oncologic treatment as well, due to a surge in electronic data, breakthroughs in technological infrastructure and groundbreaking research in deep learning neural networks. AI has demonstrated potential in improving tumor imaging diagnosis and therapy response evaluation, anticipating clinical outcomes, and accelerating drug development and translational oncology. AI has the potential to revolutionize the oncology sector, by overcoming the existing challenges, by leveraging the power of big data to further improve the cancer treatment. Although AI is already being used in oncology clinical practice, ongoing and increased efforts are required to allow AI to reach its full potential. AI in Oncology Market – Current Market Landscape Currently, over 76 industry players worldwide are actively engaged in the development of AI in oncology- based software solutions. The market is characterized by a mix of well-established and small firms. Several industry players involved in the development of AI in oncology- based software solutions are majorly providing these services for cancer diagnosis, along with drug development and drug discovery. Majority of the software providers have their platforms on cloud, for end users which include, hospitals, pharmaceutical companies and research institutes. The growing pipeline and the increasing demand for effective diagnosis of cancer indications at an early stage using AI to prevent malignancies, has spurred the establishment of many companies in the last decades; currently, AI in diagnostics market is dominated by companies based in North America, majority of them being small sized. Mutually Beneficial Partnerships in Order to Expand Capacities to Keep Pace with the Growing Demand Several partnerships have been established by various stakeholders engaged in the development of Artificial Intelligence in oncology-based software solutions in the past 5 years; there has been a significant increase in partnership activity in this domain, growing at a CAGR of 36%, during the period 2017-2022. Surge in Funding Activity in this Domain Foreseeing Lucrative Returns There has been a steady increase in the funding activity within this domain during the period 2017-2022 which amounted to more than USD 5.9 billion. High Number of Patents are Suggestive of the Widespread Research in this Domain Several industry and non-industry players are involved in the development of Artificial Intelligence in Oncology- based software solutions. Over 2,770 patents have been granted / filed by academic and industry stakeholders till date. Future Evolution of AI in Oncology Market Owing to the anticipated AI in the oncology sector and given the fact that several new players have entered the domain in the last decade, who are actively collaborating with other industry / non-industry players to expand the global reach of this domain the market opportunity associated with AI in oncology is anticipated to grow at a CAGR of 54%. For additional details, please visit https://www.rootsanalysis.com/blog/ai-in-oncology/ or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Smart Labels Market: Industry Trends and Global Forecasts, 2022-2035 2. AI-based Digital Pathology / AI Pathology Market: Industry Trends and Global Forecasts, 2022-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com